OUR PRECISION CANCER IMMUNOTHERAPIES ARE BASED ON ANCER™:
A SUPERIOR NEOANTIGEN PREDICTION PLATFORM POWERED BY MACHINE LEARNING BASED ALGORITHMS 

 

Next-generation sequencing has opened the door to precision cancer immunotherapies targeting mutations solely expressed by tumor cells.

Ancer™ prioritizes both CD8 and CD4 T cell neoepitopes. Ancer™ enables the rapid, in silico, discovery and removal of inhibitory "Self-Like" Treg neoepitopes.

Ancer™ is designed to enable the discovery of highly immunogenic neoantigens for precision cancer immunotherapies.

Learn more about Ancer™ here.

© Copyright Epivax Oncology 2019